You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Claims for Patent: 10,251,895

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,251,895

Title:	Topical compositions and methods for treating psoriasis
Abstract:	Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.
Inventor(s):	Dow; Gordon J. (Greenbrae, CA), Pillai; Radhakrishnan (Santa Rosa, CA), Bhatt; Varsha D. (San Francisco, CA)
Assignee:	Valeant Pharmaceuticals North America (Bridgewater, NJ)
Application Number:	15/173,961
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,251,895
Patent Claims:	1. A topical pharmaceutical composition for treating psoriasis the composition comprising: (a) active ingredients consisting of: (i) halobetasol propionate, at a concentration of 0.01 percent by weight of the composition; and (ii) tazarotene at a concentration of 0.045 percent by weight of the composition; and (b) a dermatologically acceptable carrier; wherein the composition is an oil-in-water emulsion; wherein an oil phase in the oil-in-water emulsion comprises a liquid oil component; wherein the liquid oil component is liquid at 22.degree. C. and consists of diethylsebacate and light mineral oil; and wherein the composition comprising the halobetasol propionate and the tazarotene at said concentrations is capable of providing synergistic efficacy and synergistic reduction of at least an adverse event selected from the group consisting of itching, burning, and stinging, for said treating. 2. The topical pharmaceutical composition of claim 1, wherein the halobetasol propionate and the tazarotene are dissolved in the liquid oil component of the emulsion. 3. The topical pharmaceutical composition of claim 2, wherein the emulsion is a lotion. 4. The topical pharmaceutical composition of claim 2, wherein the emulsion is a cream. 5. The topical pharmaceutical composition of claim 1, wherein an aqueous phase of the emulsion comprises a carbomer copolymer type B and a carbomer homopolymer type A. 6. The topical pharmaceutical composition of claim 5; wherein the diethyl sebacate is present at a concentration of 2.5-3.5 percent by weight of the composition, the light mineral oil is present at a concentration of 7.5-8.5 percent by weight of the composition, the carbomer copolymer type B is present at a concentration of 0.3-0.5 percent by weight of the composition, and the carbomer homopolymer type A is present at a concentration of 0.5-0.7 percent by weight of the composition.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.